Background: Cytomegalovirus infection manifests varying clinical characteristics and severity in diverse populations with different immune statuses. The signs and symptoms of gastrointestinal involvement are nonspecific. Here, we present a case of cytomegalovirus colitis in an immunocompetent adolescent, which manifested as intestinal pseud-obstruction. Case presentation: A 15-year-old man who had contracted novel coronavirus infection one month earlier was admitted to our hospital with fever, abdominal pain, and hematochezia. His abdomen was distended, and laboratory evaluation revealed a decrease in the blood count, an increase in inflammatory indicators and hepatic impairment. Imaging shows bowel wall thickening and dilatation of the colon. A diagnosis of intestinal infection combined with acute intestinal pseud-obstruction was made. Diarrhea persisted despite conservative treatment with empirical antibiotics. A colonoscopy was performed. Pathology confirmed cytomegalovirus infection. Ganciclovir therapy was initiated, and subsequent review showed a good recovery. Conclusions: The case was diagnosed as cytomegalovirus colitis. We reviewed the reports of 9 cases of bowel obstruction, including our own, and found that the majority of the adult patients were elderly with underlying disease. Clinical and endoscopic manifestations are typically nonspecific, and imaging shows typical signs of intestinal obstruction. The final diagnosis was confirmed by pathology. Most of them have a good prognosis. We suggest that cytomegalovirus colitis can also lead to intestinal obstruction and that viral reactivation in immunocompetent individuals may be associated with inflammatory conditions and viral coinfection, particularly with the novel coronavirus.
18 December 2025 in International Urology and Nephrology
Background Acute kidney injury (AKI) is a common and serious complication in critically ill patients, significantly associated with increased mortality. This systematic review and meta-analysis evaluates the impact of protein intake on the incidence of renal adverse events in this population. Methods We included randomized controlled trials (RCTs) comparing higher (> 1.3 g/kg/day) versus lower (≤ 1.3 g/kg/day) protein intake in adult intensive care patients. PubMed, Embase, and Web of Science were searched from 1980 to April 2025. The risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB2) tool. Random-effects models were used to calculate the pooled odds ratio (OR) with 95% confidence intervals(CI). The primary outcome was renal adverse events, defined as AKI or renal replacement therapy (RRT). Secondary outcomes included 28-day, intensive care unit (ICU), and hospital mortality. Results Fourteen RCTs including 7,280 patients were analyzed. Higher protein intake was associated with a lower risk of renal adverse events (OR 0.86, 95% CI 0.76–0.98; P = 0.02; I2 = 0%). No significant effect was observed on renal replacement therapy (OR 1.20, 95% CI 0.89–1.61; P = 0.23), 28-day mortality (OR 0.76, 95% CI 0.50–1.15; P = 0.19), ICU mortality (OR 0.82, 95% CI 0.62–1.09; P = 0.17), or hospital mortality (OR 0.93, 95% CI 0.65–1.33; P = 0.70). Sensitivity analyses indicated that the renal benefit was largely driven by a single large RCT. Conclusions Protein intake exceeding 1.3 g/kg/day is associated with a lower incidence of renal adverse events in critically ill patients, but shows no significant association with a survival advantage. These findings support tailoring protein targets to balance nutritional adequacy against renal burden. Large-scale multicenter trials are needed to establish safe and effective protein thresholds. Registration of systematic reviews The protocol for this meta-analysis was prospectively registered in PROSPERO (CRD420250636693).